This book provides an up-to-date review of current management techniques for Non-Small Cell Lung Cancer. It addresses all of the latest issues that have been raised by the discovery of oncogenic drivers and the improvement of diagnosis and therapeutic methods, including new radiotherapy techniques and anticancer strategies like immunotherapy. New strategies for patients with molecular alterations and the management of particular types of cases are also highlighted. Written by recognized experts in their field, the book represents a unique and valuable resource in the field of lung cancer, both for those currently in training and for those already in clinical or research practice.

Cancer is the second leading cause of death among adults in the United States after heart disease. However, improvements in cancer treatment and earlier detection are leading to growing numbers of cancer survivors. As the number of cancer survivors grows, there is increased interest in how cancer and its treatments may affect a person's ability to work, whether the person has maintained employment throughout the treatment or is returning to work at a previous, current, or new place of employment. Cancer-related impairments and resulting functional limitations may or may not lead to disability as defined by the U.S. Social Security Administration (SSA), however, adults surviving cancer who are unable to work because of cancer-related impairments and functional limitations may apply for disability benefits from SSA. At the request of SSA, Diagnosing and Treating Adult Cancers and Associated Impairments provides background information on breast cancer, lung cancer, and selected other cancers to assist SSA in its review of the listing of impairments for disability assessments. This report addresses several specific topics, including determining the latest standards of care as well as new technologies for understanding disease processes, treatment modalities, and the effect of cancer on a person's health and functioning, in order to inform SSA's evaluation of disability claims for adults with cancer.

Nanotechnology-based Targeted Drug Delivery Systems for Lung Cancer is an indispensable resource that will help pharmaceutical scientists and clinical researchers design and develop novel drug delivery systems and devices for the treatment of lung cancer. As recent breakthroughs in nanomedicine are now making it possible to deliver drugs, genes and therapeutic agents to localized areas of disease to maximize clinical benefit, while also limiting unwanted side effects, this book explores promising approaches for the diagnosis and treatment of lung cancer using cutting-edge nanomedical technologies. Topics discussed include polymeric nanoparticles, solid lipid nanoparticles, liposomes, dendrimers, micelles and nanoemulsions. - Provides an overview of an array of nanotechnology-based drug delivery systems - Examines the design, synthesis and application of different nanocarriers in drug and gene delivery - Provides an in-depth understanding of the design of targeted nanotherapeutics and technologies and its implication in various site-specific cancers

with contributions by Pathologists from 14 Countries

The book comprehensively reviews and provides detailed insight into the cellular and molecular signalling mechanisms involved in pathophysiology of various respiratory diseases, towards developing effective therapeutic strategies in the management and treatment of lung disease. It also covers promising advances in the field of therapeutics that could lead to novel clinical therapies capable of preventing or reversing the disease features including novel strategies for targeting chronic lung diseases using advanced drug delivery systems. Importantly, the book examines the significance and relevance of the plant extracts and their constituents with therapeutic efficiencies against lung diseases. As such, the book offers a blend of translational, biological, chemical, and drug delivery aspects relevant to respiratory diseases, thus, offering a valuable resource for pulmonologists and translational researchers working in the field of pulmonary biology and respiratory medicine.

This book describes the molecular mechanisms of lung cancer development and progression that determine therapeutic interventions in the era of genomics, when the rapid evolution in lung cancer diagnosis and treatment necessitates critical review of new results to integrate advances into practice. The text opens with background and emerging information regarding the molecular biology of lung cancer pathogenesis. Updated results regarding lung cancer prevention and screening are discussed, followed by chapters on diagnostic techniques and pathological evaluation. This leads on to a detailed presentation of treatment modalities, from surgery and radiation therapy to standard chemotherapy and targeted agents. The coverage includes resistance to therapy and the emergence of immunotherapy for lung cancer; in addition, the current evidence in respect of small cell lung cancer is summarized. The book presents insights from experts across disciplines to emphasize the importance of collaborative care. Advances in our understanding of issues in geriatric oncology and palliative care complete the comprehensive discussion of lung cancer.

This, the first of two volumes on personalized medicine in lung cancer, touches on the core issues related to the understanding of lung cancer—statistics and epidemiology of lung cancer—along with the incidence of lung cancer in non-smokers. A major focus of this volume is the state of current therapies against lung cancer—immune, targeted therapies against EGFR TKIs, KRAS, ALK, angiogenesis; the associated challenges, especially resistance mechanisms; and recent progress in targeted drug development based on metal chemistry. Chapters are written by some of the leading experts in the field, who provide a better understanding of lung cancer, the factors that make it lethal, and current research focused on developing personalized treatment plans. With a unique mix of topics, this volume summarizes the current state-of-knowledge on lung cancer and the available therapies.